Symptom-based progression-free survival (S-PFS) as a clinically relevant and patient-centric endpoint in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Results from the ALPINE trial
Year: 2025
Type: conference-abstract
Source: Blood
Institutions: Dana-Farber Cancer Institute, University of Pennsylvania, Herbert Irving Comprehensive Cancer Center, Columbia University, Monash University, Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Hematology & Blood Diseases Hospital, BeOne Medicines (Switzerland), University of Washington, Fred Hutch Cancer Center
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417016183
Cites:
Cited by:
Related to: